不感兴趣
发表于 2025-3-26 21:46:47
http://reply.papertrans.cn/88/8737/873666/873666_31.png
LIMIT
发表于 2025-3-27 01:51:53
http://reply.papertrans.cn/88/8737/873666/873666_32.png
运气
发表于 2025-3-27 07:24:59
http://reply.papertrans.cn/88/8737/873666/873666_33.png
NAG
发表于 2025-3-27 13:08:22
http://reply.papertrans.cn/88/8737/873666/873666_34.png
intimate
发表于 2025-3-27 16:56:00
http://reply.papertrans.cn/88/8737/873666/873666_35.png
mercenary
发表于 2025-3-27 19:10:30
http://reply.papertrans.cn/88/8737/873666/873666_36.png
辩论的终结
发表于 2025-3-28 00:59:38
http://reply.papertrans.cn/88/8737/873666/873666_37.png
有角
发表于 2025-3-28 03:48:10
Barbara Brokamp result in substantially higher numbers of non-small cell lung cancer (NSCLC) patients and especially elderly patients with stage I NSCLC. An aging population will increase the number of NSCLC patients by 50 % in the US and the majority of these patients will be older than 65 years. CT based screeni
表皮
发表于 2025-3-28 07:48:57
Mara Westling Allodill survival in the order of 70 %, 12 months, and 2 years, respectively. First-line treatment is preferred as ORR, PFS, and quality of life are improved compared to chemotherapy. Gefitinib and erlotinib are referred to as first-generation EGFR TKIs. The second-generation TKIs afatinib and dacomitinib
焦虑
发表于 2025-3-28 12:46:49
http://reply.papertrans.cn/88/8737/873666/873666_40.png